← Back to graph
Prescription

omalizumab chronic rhinosinusitis

Selected indexed studies

  • Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy. (Int Forum Allergy Rhinol, 2024) [PMID:37394893]
  • Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design. (Am J Rhinol Allergy, 2022) [PMID:35837739]
  • Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. (Lancet Respir Med, 2025) [PMID:41033334]

_Worker-drafted node — pending editorial review._

Connections

omalizumab chronic rhinosinusitis is a side effect of

Sources

Local graph